The FDA granted regenerative medicine advanced therapy designation to 4D-150 for the treatment of diabetic macular edema, ...

D-150 is a potential backbone therapy that is designed to provide multi-year sustained delivery of anti-VEGF (aflibercept and ...

The therapy leverages the company’s intravitreal vector, R100, invented using the Therapeutic Vector Evolution platform.

Medically reviewed by Andrew Greenberg, MD Optometrists (healthcare providers who offer standard eye care) can diagnose wet age-related macular degeneration (AMD) but can't treat it. Therapies for wet ...

Another complete response letter from the U.S. FDA for Regeneron Pharmaceuticals Inc.’s age-related macular degeneration (AMD) therapy Eylea (aflibercept) – along with disappointing sales of the VEGF ...

Patients with neovascular age-related macular degeneration (nAMD) experienced improvements in central macular thickness and ...

Clinical trial of KH658 evaluates single suprachoroidal space administration of gene-therapy treatment for wet AMD CHENGDU, China and ROCKA ...

A single intravitreal injection of UBX1325 (foselutoclax) was shown to be safe in patients with diabetic macular edema. The ...

Wet AMD is the leading cause of vision loss in the ... it is also seeing a challenge in the market from Roche with its bispecific VEGF and Ang-2 inhibitor Vabysmo (faricimab), which can be dosed ...

D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment ...

Diabetic macular edema is a complication that develops from diabetic retinopathy, a widespread consequence of diabetes and a ...